Clovis Oncology Inc CLVS is trading higher Thursday morning after the company announced data from the monotherapy arm of the ATHENA trial achieved the primary endpoint of significantly improved investigator-assessed progression-free survival compared with the placebo.
Based on the results, Clovis plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration during the second quarter.
The sNDA submission will be followed by a Type II Variation in the third quarter for a first-line maintenance treatment indication for women with advanced ovarian cancer who have responded to first-line platinum-based chemotherapy regardless of biomarker status.
Clovis is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents.
CLVS 52-Week Range: $1.35 - $7.35
The stock was up 47.3% at $2.43 at time of publication.
Photo: fernandozhiminaicela from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.